Pharma BD Deal Intelligence
Forest never got the chance to run its own thesis—Actavis acquired Forest just five months after the $2.9B Aptalis close, and Aptalis's pieces were subsequently carved up: manufacturing sold off in 2015, Ultresa discontinued in 2016, and Zenpep/Viokace divested to Nestlé in 2020 as an antitrust condition of AbbVie-Allergan.
TPG Capital exit at $2.9B, characterized by Bloomberg as a clean PE-to-strategic handoff with Forest CEO Brent Saunders citing immediate accretion.
Deal closed Feb 3, 2014 strengthening Forest's US/Canada GI franchise and adding US/EU CF business — financed via cash + $1.8B bond offering.
Six weeks after closing Aptalis, Forest itself was acquired by Actavis for ~$25B — Aptalis assets moved up the chain to Actavis/Allergan within months.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Forest Laboratories agreed to acquire privately held Aptalis for $2.9B in cash from TPG Capital, strengthening Forest's U.S. and Canadian gastrointestinal franchise and adding a U.S./European cystic fibrosis business. Deal closed February 3, 2014; Forest itself was acquired by Actavis four months later.
Assessment window: 5yr post-close.
$700M Aptalis revenue contribution to Forest (~$700M FY15 expected)
Aptalis spanned two distinct GI franchises: (1) exocrine pancreatic insufficiency in cystic fibrosis (ZENPEP), affecting 80-90% of the ~30,000+ US CF patient population per CFF Registry; and (2) specialty GI products including CANASA (rectal mesalamine for distal ulcerative colitis) and CARAFATE (sucralfate for duodenal ulcer). Both categories require lifetime therapy with strong physician loyalty and meaningful pricing power.
ZENPEP competes in the US pancreatic enzyme replacement therapy (PERT) category alongside AbbVie's Creon (category leader, ~50%+ share post-2009 reformulation), Janssen's Pancreaze, Digestive Care's Pertzye, and (briefly) Aptalis's own Ultresa — all FDA-approved between 2009 and 2012 after the agency required all PERTs to obtain NDAs. Clinical equipoise between Creon and ZENPEP (no efficacy difference, lower AE rate for ZENPEP per comparator trials) means the category competes on contracting and physician familiarity. CANASA leads US rectal mesalamine alongside Salix's Rowasa enema and Shire's Lialda oral mesalamine; the broader UC market was valued at ~$5.9B in the US (DelveInsight) with aminosalicylates a $2.8B segment globally (2024). Forest's strategic logic was franchise concentration in GI — bolting Aptalis onto Linzess (linaclotide for IBS-C, partnered with Ironwood) and Saphris/Viibryd to create a US/EU GI specialty platform with ~$700M in incremental revenue and $0.78 EPS accretion. The deal closed February 3, 2014; less than four months later, Actavis acquired Forest for ~$25B (announced Feb 18, 2014), so Aptalis's strategic value transferred to Actavis (later Allergan, then Teva for Allergan generics), and the Aptalis assets were ultimately part of the portfolio rationalization that accompanied the Allergan/Teva $40.5B deal in 2016.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Forest Laboratories, Inc. / Aptalis Pharma Inc. (this deal) | 2014 | $2.9B | 25 |
| Forest Laboratories, Inc. / Cerexa Inc. | 2006 | $580M | 47 |
| Forest Laboratories, Inc. / Clinical Data, Inc. | 2011 | $1.2B | 37 |
| UCB SA / Celltech Group plc | 2004 | $2.7B | 92 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
← Browse all deals · How we score deals
More: 2014 deals · Forest Laboratories, Inc. deals · Gastroenterology deals